Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Shortened Regimens for Pulmonary TB
NCT02901288Phase 4Unknown
- Sponsor
- Beijing Chest Hospital
- Start
- Aug 2016
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of levofloxacin in pulmonary tuberculosis (TB) (3 arms), sponsored by Beijing Chest Hospital. Primary endpoints: Percentage of participants with TB recurrence/relapse and Percentage of participants with treatment failure at 6 months. Status: unknown.
02
Drugs
levofloxacin
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT02901288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02901288.